GLP-1 (glucagon-like peptide-1) is an incretin hormone produced by L-cells in the small intestine in response to nutrient ingestion. Its receptor — the GLP-1 receptor (GLP-1R) — is expressed in pancreatic beta cells, the central nervous system, cardiac tissue, and peripheral organs involved in energy regulation. Understanding GLP-1 signaling pathways is foundational to metabolic peptide research.

GLP-1 Receptor Signaling Cascade

GLP-1R activation couples to Gs proteins, stimulating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA) and exchange proteins activated by cAMP (Epac), which promote insulin exocytosis in a glucose-dependent manner. This glucose-dependence is a key research interest — GLP-1 analogs stimulate insulin release only when glucose is elevated, a mechanism studied for its relevance to metabolic homeostasis.

Incretin Effect Research

The incretin effect — the enhanced insulin response to oral vs. intravenous glucose — is partly mediated by GLP-1. Research peptides modeled on GLP-1 are used to study the incretin effect in cell systems, isolating the contribution of GLP-1R signaling from other factors. This includes research into GIP (glucose-dependent insulinotropic polypeptide) co-agonism and the additive effects observed with dual GLP-1/GIP compounds.

Multi-Receptor Pathway Studies

Dual (GLP-1/GIP) and triple (GLP-1/GIP/glucagon) agonist compounds allow researchers to map additive or synergistic receptor interactions. Tirzepatide-class compounds activate both GLP-1R and GIPR, producing downstream signaling profiles studied for differentiated metabolic outcomes compared to GLP-1-only compounds. Retatrutide-class triple agonists add glucagon receptor activation, introducing energy expenditure and lipolysis pathway dimensions to the research.

Research use only. Not for human or animal use.